U.S. News Room
December 22, 2025
NEW
ENHERTU Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Download
December 22, 2025
NEW
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Download
December 15, 2025
NEW
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
December 09, 2025
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Download
December 08, 2025
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
Download
December 03, 2025
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Download
November 10, 2025
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
October 30, 2025
DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Download